Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial

William G. Herrington; Christoph Wanner; Parminder K. Judge; Kaitlin J. Mayne; Doreen Zhu; Natalie Staplin; David Preiss; Will Stevens; Karl Wallendszus; Carol Knott; Michael D. Hill; Jonathan Emberson; Vladimir Cejka; Alfred K. Cheung; Jing Li; Lai Seong Hooi; Wen Liu; Masaomi Nangaku; Adeera Levin; David Z.I. Cherney; Roberto Pontremoli; Aldo Maggioni; Shinya Goto; Aiko Tomita; Rajat Deo; Katherine R. Tuttle; Jens Eilbracht; Mark Hopley; Martin Landray; Colin Baigent; Richard Haynes; Colin Baigent; Martin Landray; Christoph Wanner; William G. Herrington; Richard Haynes; Martina Brueckmann; Mark Hopley; Alfred K. Cheung; David Preiss; Jing Li; Lai Seong Hooi; Wen Liu; Masaomi Nangaku; Adeera Levin; David Z.I. Cherney; Roberto Pontremoli; Aldo Maggioni; Natalie Staplin; Jonathan Emberson; Shinya Goto; Rajat Deo; Katherine R. Tuttle; Francisco Javier Rossello Lozano; Doreen Zhu; Peter Sandercock; Rudolf W. Bilous; Charles A. Herzog; Paul K. Whelton; Janet Wittes; Derrick Bennett; Andy Burke; R. H. Brown; Lucy Fletcher; Hannah Gosling; Emily Harding; Richard Haynes; William G. Herrington; Parminder K. Judge; Carol Knott; Ryonfa Lee; Kevin Murphy; R Raff; Hui Yu; Vladimir Cejka; Marcela Fajardo-Moser; Andrea Lorimer; Donata Lucci

doi:10.1093/ndt/gfac040

Abstract

1 min read

EMPA-KIDNEY will evaluate the efficacy and safety of empagliflozin in a widely generalizable population of people with CKD at risk of kidney disease progression. Results are anticipated in 2022.

Related publications

Letter2019

Reducing Risk of Adverse Cardiovascular and Renal Outcomes for Patients with Atrial Fibrillation and Type 2 Diabetes

Stephanie L. Harrison, Deirdre A. Lane, Professor Gregory Lip

Preprint2024

A genetic and clinical risk factor algorithm to aid in identifying new cases of chronic kidney disease from the general population

Graham E.L Rodwell, John P A Ioannidis, Stuart K. Kim

Article2023

Drugs with a negative impact on cognitive function (Part 1): chronic kidney disease as a risk factor

Sophie Liabeuf, Vesna Pešić, Goce Spasovski, Romaldas Mačiulaitis, Mickaël Bobot, Ana Farinha, Carsten A. Wagner, Robert J. Unwin, Giovambattista Capasso, Inga Arūnė Bumblytė, Gaye Hafez, Giovambattista Capasso, Alexandre Andrade, Maie Bachmann, Inga Arūnė Bumblytė, Adrian Covic, Pilar Delgado, Nicole Endlich, Andreas Engvig, Denis Fouque, Casper Franssen, Sebastian Frische, Liliana Gârneaţă, Loreto Gesualdo,

Article2017

Cost-effectiveness analysis of empagliflozin in the treatment of patients with type 2 diabetes and established cardiovascular disease in Italy, based on the results of the EMPA-REG OUTCOME study

Sergio Iannazzo, Edoardo Mannucci, Odette S. Reifsnider, Aldo Maggioni

Article2025

#2929 Early versus delayed anticoagulation in acute ischaemic stroke in those with chronic kidney disease: a pre-specified subgroup analysis of the OPTIMAS randomised controlled trial

Philip S. Nash, Hakim‐Moulay Dehbi, Jonathan G. Best, David Cohen, Martin James, Professor Gregory Lip, Bo Norrving, Nikola Sprigg, Nick Freemantle, David C. Wheeler, David J. Werring